Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
The role of surgery in the management of metastatic melanoma is reviewed. Favorable prognostic factors include a longer disease free interval, single site of disease, complete resection, and nonvisceral metastases. Patients undergoing complete resection of remote nonvisceral metastases have a median survival of 17-50 months, and a 5-year survival (5YS) of 9-35%. Patients with pulmonary metastases are usually asymptomatic; complete resection results in a median survival of 8-20 months, and a 5YS of 10-25%. In contrast, patients with metastases to brain or gastrointestinal tract are usually symptomatic; resection offers good palliation, but their median survival is only 7-10 months with few long-term survivors. The key to effective surgical management of patients with metastatic melanoma is careful patient selection.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on